Medical Device Translation and EU MDR / UK MDR Compliance: 2026 Guide

Medical Device Translation and EU MDR / UK MDR Compliance: 2026 Guide

TL;DR — EU Medical Device Regulation (EU MDR, Regulation 2017/745) requires medical device labelling, Instructions for Use (IFU) and patient-facing documentation to be translated into the official languages of every EU member state where the device is marketed — up to 24 languages. Post-Brexit, the UK has the separate UK MDR framework with its own requirements. Medical device translation must be done by qualified medical translators, undergo review by a second linguist, and be produced under ISO 17100 and ISO 13485 quality frameworks. Errors can trigger regulatory non-compliance, recall or liability claims.

Medical device translation is one of the most regulated and technically demanding areas of professional translation. The consequences of error are not hypothetical: mistranslation of Instructions for Use has led to device recalls, regulatory enforcement and patient harm. This guide explains what EU MDR and UK MDR actually require, the technical framework underpinning compliant translation, and how manufacturers should select a translation provider.

What are the EU MDR translation requirements?

Regulation (EU) 2017/745 on medical devices (EU MDR), which became fully applicable on 26 May 2021 with extended transition periods, requires that specific categories of information accompanying medical devices be translated into the official language(s) of every EU member state where the device is placed on the market.

Article 10(11) of EU MDR requires manufacturers to ensure that "the device is accompanied by the information set out in Section 23 of Annex I in an official Union language(s) determined by the Member State in which the device is made available to the user or patient."

This applies to:

• Labelling on the device itself and its packaging.
• Instructions for Use (IFU), whether paper or electronic.
• Implant cards for implantable devices.
• Patient information leaflets for devices intended for lay users.
• Summary of Safety and Clinical Performance (SSCP) for Class III and implantable devices, which must be publicly available on EUDAMED.
• Declaration of Conformity, for Notified Body submissions.

For professional-use devices, each member state can specify whether translation is required or whether English is acceptable for healthcare professionals. In practice, most EU member states require their national language.

For lay-use devices (over-the-counter, home-use, patient-operated), the official language(s) of the member state is almost always mandatory.

Which 24 EU languages does MDR require?

The EU has 24 official languages, and manufacturers selling devices across the EU may need all of them:

Bulgarian, Croatian, Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Hungarian, Irish, Italian, Latvian, Lithuanian, Maltese, Polish, Portuguese, Romanian, Slovak, Slovenian, Spanish, Swedish.

Whether you need all 24 depends on which markets you sell in. A typical mid-size European medical device manufacturer covering the main EU markets translates into 8–12 languages; a pan-EU player covers all 24.

Some member states also require Norwegian (EEA), Icelandic (EEA), and in some cases regional languages like Catalan or Basque for patient-facing materials.

How does UK MDR differ from EU MDR for translation?

Since Brexit, the UK has its own medical device regulatory framework, administered by the Medicines and Healthcare products Regulatory Agency (MHRA).

Great Britain (England, Scotland, Wales):

• Regulated under UK Medical Devices Regulations 2002 (as amended).
• UKCA marking required (UKCA certificates) alongside or replacing CE marking.
• Labelling and IFU must be in English.
• Timeline for transition from CE marking to UKCA marking has been extended multiple times; current legislation permits continued acceptance of CE-marked devices until at least 30 June 2030 for certain categories. Verify current timelines at gov.uk/mhra.

Northern Ireland:

• Operates under the EU MDR framework due to the Northern Ireland Protocol / Windsor Framework.
• CE marking and EU MDR translation requirements continue to apply.
• Effectively, devices sold in Northern Ireland must meet EU MDR language requirements (English plus any other local requirement); devices sold only in GB must meet UK MDR (English).

For manufacturers selling across the UK and EU, the pragmatic approach is to translate for EU MDR compliance and retain English for UK MDR — which covers Northern Ireland and GB simultaneously.

What is a medical device IFU (Instructions for Use) translation?

The Instructions for Use (IFU) is the primary document accompanying a medical device. It is the regulated text that tells the user how to use the device safely.

Under EU MDR Annex I, Section 23.4, the IFU must contain specific information including:

• Intended purpose of the device.
• Intended users and patient populations.
• Contra-indications and warnings.
• Step-by-step instructions for correct use.
• Cleaning, disinfection and maintenance procedures where applicable.
• Residual risks and side-effects.
• Information on incident reporting.

All of this must be translated accurately, with terminology consistent with clinical practice in each target language. Translation quality affects:

• Regulatory approval. Notified Bodies review translations for compliance during conformity assessment.
• Post-market surveillance. Patient complaints often arise from IFU confusion; mistranslations show up in incident reports.
• Product liability. In litigation, a mistranslated warning can be the deciding factor in establishing manufacturer liability.

A single-language IFU for a Class IIa device typically runs 20–80 pages. Translation into 12 languages can easily be a 250,000-word project, priced in the £25,000–£60,000 range depending on complexity and language pairs.

Who is qualified to translate medical device documentation?

Medical device translation requires qualified medical translators working within structured quality frameworks. The minimum credentials expected by Notified Bodies and serious manufacturers:

Translator qualifications:

• Native speaker of the target language.
• Degree or professional qualification in translation (CIOL Diploma, university-level translation studies).
• Specialist qualification or demonstrable experience in medical / life sciences translation.
• Familiarity with EU MDR, ISO 14971 (risk management), and IEC 62366 (usability engineering) terminology.

Provider framework:

• ISO 17100 — the international standard for translation services, mandating translator qualifications, revision processes and project management.
• ISO 13485 — quality management for medical devices; some manufacturers require their translation vendors to hold this or an equivalent.
• ISO 18587 — for providers offering post-edited machine translation, defining human revision requirements.

Process requirements:

• Two-step translation + revision — the initial translation is reviewed by a second qualified linguist.
• Terminology management — glossaries and translation memories maintained per client / device family.
• In-country review — where available, subject matter experts in the target market review the translation for clinical accuracy.
• Back-translation (occasional, for high-risk content) — the translated text is translated back into the source language by a third translator to verify meaning preservation.

Providers that cannot demonstrate these frameworks should not be used for MDR-regulated work. The cost differential between a qualified medical device translation provider and a general translator is significant — but the risk differential is larger still.

Common compliance pitfalls

Six issues that trigger regulatory problems or rejection by Notified Bodies:

1. Inconsistent terminology across languages. A warning that uses one term in German and a different synonym in Italian creates a compliance issue. Use of glossaries and translation memories prevents this.

1. Outdated terminology. Medical device regulation has evolved; terms like "Adverse Event Reporting" have specific MDR meanings. Translations using pre-MDR legacy terminology can fail review.

1. Symbols translated instead of retained. Standardised symbols under ISO 15223-1 should remain unchanged — only their accompanying text is translated. Translating a symbol's visual element is a non-compliance.

1. Regulatory references not updated. Old translations still reference the Medical Device Directive (MDD, 93/42/EEC) instead of MDR. These references must be updated in full.

1. Labelling truncated. Packaging space limits sometimes mean labels are abbreviated in one language and not another. The regulatory requirement is that all mandatory information is present and legible in every language.

1. Electronic IFU without language switching. Under Regulation (EU) 2021/2226, professional-use devices can use electronic IFU, but the eIFU must offer all required languages. Missing language versions is a compliance failure.

UK MDR 2025/2026 landscape

The UK government has been progressing reform to UK MDR 2002. Key 2025–2026 developments to be aware of:

• Post-market surveillance regulations came into force in June 2025, with specific requirements for incident reporting that include linguistic accessibility.
• Updated requirements for UKCA marking with extended recognition of CE marking under certain conditions until at least 30 June 2030.
• Northern Ireland continues to follow EU MDR under the Windsor Framework; GB follows UK MDR.

The UK MHRA has signalled further reform aligning with some EU MDR provisions while diverging in others. Manufacturers selling in both the UK and EU should maintain dual compliance strategies and translation workflows capable of serving both regimes.

Cost benchmarks for medical device translation

Indicative 2026 pricing for medical device translation:

• Simple labelling: Per word (source) £0.14–£0.20; Typical IFU cost per language £50–£200
• Standard IFU (Class I/IIa): Per word (source) £0.16–£0.22; Typical IFU cost per language £500–£3,500
• Complex IFU (Class IIb/III): Per word (source) £0.18–£0.26; Typical IFU cost per language £2,000–£8,000
• SSCP (Summary of Safety & Clinical Performance): Per word (source) £0.20–£0.28; Typical IFU cost per language £1,000–£4,000
• Risk management file (Class III): Per word (source) £0.22–£0.32; Typical IFU cost per language £5,000–£15,000

For multi-language projects, volume discounts of 10–25% typically apply, and translation memory reuse on related products reduces cost further.

Back-translation (where required for validation) adds approximately 40–60% to the single-direction cost.

Frequently asked questions

Do I need to translate for every EU country or just the ones I sell in? Only the ones where the device is placed on the market. Member states determine their own language requirements — verify the specific national authority's published list before finalising scope.

Can machine translation be used for medical device IFU? MT is increasingly used in the translation workflow, but always with human post-editing by qualified medical translators under ISO 18587. Pure raw MT is not compliant with ISO 17100 or MDR expectations for patient-facing content.

What is required for clinical evaluation documentation? Clinical evaluation documents submitted to Notified Bodies are typically accepted in English, but translations are often required for specific member state authorities during conformity assessment or surveillance.

How often should translations be updated? Whenever the source document changes materially. Regulatory updates (e.g. MDR amendments), changes to intended use, new contra-indications, or added features all trigger re-translation.

Is there a specific Notified Body-approved translator list? No single pan-EU list exists. Notified Bodies expect ISO 17100 compliance from translation providers but do not pre-approve individual vendors.

What happens if a translation error is discovered after market placement? The manufacturer must assess the risk and take action under their Post-Market Surveillance system, which may include field safety notices, label corrections, or in severe cases, recall. MHRA and EU competent authorities must be notified in accordance with incident reporting rules.

Does Northern Ireland follow EU MDR or UK MDR? Under the current Windsor Framework arrangements, Northern Ireland follows EU MDR for medical devices. Manufacturers selling in Northern Ireland must meet EU MDR translation and marking requirements.

This guide reflects EU MDR and UK MDR requirements as of 2026. The regulatory environment — particularly UK MDR post-Brexit — continues to evolve. Verify current requirements with the MHRA (gov.uk/mhra) and the relevant EU competent authorities before finalising compliance strategy.